Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression With Tacrolimus, Mycophenolic Acid and Corticosteroids

The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:
How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?
How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.
How does the body respond to siplizumab after dosing at each of the 2 dose levels?
How does siplizumab work in the body compared to rATG?
Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.
Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.
Participants will be monitored for 12 months after transplant surgery.

开始日期2026-06-29

申办/合作机构

Nefro Avillion Clinical Development

NCT06972069

/ Recruiting早期临床1期IIT

Tolerance Through Mixed Chimerism (Sip-Tego)

This is an open-label, single-institution study to assess the safety and the efficacy of the Sip-Tego regimen for the induction of donor-specific immunologic unresponsiveness to a renal allograft. The investigators propose to treat 6 adult subjects in end-stage renal disease (ESRD) who do not demonstrate evidence of prior sensitization.

开始日期2025-05-31

申办/合作机构

The Massachusetts General Hospital

[+2]

NCT06326476

/ Recruiting早期临床1期IIT

An Open-label Parallel Group Pilot Study to Demonstrate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa

This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.

开始日期2025-05-09

申办/合作机构

The University of Alabama at Birmingham

[+1]

100 项与希普利珠单抗相关的临床结果

登录后查看更多信息

100 项与希普利珠单抗相关的转化医学

登录后查看更多信息

100 项与希普利珠单抗相关的专利（医药）

登录后查看更多信息

项与希普利珠单抗相关的文献（医药）

2020-01-01·Scandinavian journal of immunology4区 · 医学

Pharmacokinetic and pharmacodynamic study of a clinically effective anti‐CD2 monoclonal antibody

4区 · 医学

Article

作者: Sykes, Megan ; Berglund, David ; Berglund, Erik ; Griesemer, Adam ; Fontenot, Jane ; Sachs, David H. ; Binder, Christian ; Hope, James ; Sellberg, Felix

Abstract:

The humanized IgG1κ monoclonal antibody siplizumab and its rat parent monoclonal IgG2b antibody BTI‐322 are directed against the CD2 antigen. Siplizumab is species‐specific, reacting with human and chimpanzee cells but not with cells from any other species, including other non‐human primates. Because siplizumab treatment has recently shown great potential in clinical transplantation, we now present the results of our previous pharmacokinetic, pharmacodynamic and safety studies of both antibodies. Fourteen chimpanzees received 1‐3 doses of 0.143 to 5.0 mg/kg iv The effects were followed with flow cytometry on peripheral lymphocytes and staining of lymph nodes. Side effects were recorded. Serum antibody concentrations were followed. Across the doses, a rapid, transient depletion of CD2, CD3, CD4 and CD8 lymphocytes and NK cells was observed for both antibodies. Immune reconstitution was more rapid for BTI‐322 compared to siplizumab. Paracortical lymph node T cell depletion was moderate, estimated at 45% with doses of >0.6 mg/kg. Restoration of lymph node architecture was seen after two weeks to two months for all animals. All four subjects receiving BTI‐322 experienced AEs on the first dosing day, while the eight subjects dosed with siplizumab experienced few mild, transient AEs. Infusion with siplizumab and BTI‐322 resulted in rapid depletion of CD2+ cells in circulation and tissue. Siplizumab had a longer t1/2 and fewer AEs compared to BTI‐322.

2020-01-01·American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons1区 · 医学

Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro

1区 · 医学

Article

作者: Brittany Shonts ; Christian Binder ; Aleksandar Obradovic ; Susan DeWolf ; Megan Sykes ; Felix Sellberg ; Manuel A. Podestà ; Nichole Danzl ; Siu-Hong Ho ; Elizabeth Waffarn ; David Berglund

Siplizumab, a humanized anti-CD2 monoclonal antibody, has been used in conditioning regimens for hematopoietic cell transplantation and tolerance induction with combined kidney-bone marrow transplantation. Siplizumab-based tolerance induction regimens deplete T cells globally while enriching regulatory T cells (Tregs) early posttransplantation. Siplizumab inhibits allogeneic mixed-lymphocyte reactions (MLRs) in vitro. We compared the impact of siplizumab on Tregs versus other T cell subsets in HLA-mismatched allogeneic MLRs using PBMCs. Siplizumab predominantly reduced the percentage of CD4⁺ and CD8⁺ effector memory T cells, which express higher CD2 levels than naïve T cells or resting Tregs. Conversely, siplizumab enriched proliferating CD45RA^- FoxP3^HI cells in MLRs. FoxP3 expression was stable over time in siplizumab-containing cultures, consistent with enrichment for bona fide Tregs. Consistently, high-throughput TCRβ CDR3 sequencing of sorted unstimulated and proliferating T cells in MLRs revealed selective expansion of donor-reactive Tregs along with depletion of donor-reactive CD4⁺ effector/memory T cells in siplizumab-containing MLRs. These results indicate that siplizumab may have immunomodulatory functions that may contribute to its success in tolerance-inducing regimens. Our studies also confirm that naïve in addition to effector/memory T cells contribute to the allogeneic MLR and mandate further investigation of the impact of siplizumab on alloreactive naïve T cells.

2018-06-03·Leukemia & lymphoma

Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas

Letter

作者: Steinberg, Seth M. ; Wilson, Wyndham H. ; Roschewski, Mark ; Lucas, Andrea ; Pittaluga, Stefania ; Jaffe, Elaine S. ; Melani, Christopher ; Waldmann, Thomas A. ; Roswarski, Joseph

The author investigates about the effect of anti-CD2 monoclonal antibody such as siplizumab with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-RS) in patients with untreated aggressive peripheral T-cell lymphoma.Feasibility and safety of administering dose-adjusted EPOCH-RS was assessed.Patients with untreated, mature T- and NK-cell lymphomas expressing CD2 in at least thirty percent of malignant cells were enrolled.Siplizumab was given day 1 of each cycle followed by dose-adjusted EPOCH-R on days 1-5 for a 21-day cycle.Dose-limiting toxicity (DLT) for siplizumab was defined as infusionalgrade 3 non-hematol. toxicity lasting longer than 6 h after the infusion, any grade 4 non-hematol. toxicity, or the development of an EBV-related lymphoproliferative disorder.The probability of OS and PFS as a function of time was estimated by the Kaplan-Meier method.Toxicity was assessed in all 14 treated patients and in each of 75 cycles of dose-adjusted EPOCH-RS administered.Toxicity profile of EPOCH-RS showed no unanticipated dose limited toxicities.The result indicate that dose-adjusted anti-CD2 monoclonal antibody such as siplizumab therapy with EPOCH-R was well-tolerated and had an ORR of 84.5 percent in untreated patients with aggressive peripheral T-cell lymphomas.

项与希普利珠单抗相关的新闻（医药）

2025-06-12

·PRNewswire

4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus host disease market and creating significant growth opportunities. LAS VEGAS, June 12, 2025 /PRNewswire/ -- Graft versus host disease (GvHD) is an immune-driven disorder caused by a complex interplay between the donor's and recipient's adaptive immune systems. It typically manifests in two main forms: acute (aGvHD) and chronic (cGvHD). As per DelveInsight's analysis, approximately 60,000 allogeneic transplants and around 55,000 GvHD cases occurred in the 7MM in 2024. These numbers are projected to grow at a notable CAGR over the forecast period from 2025 to 2034. Corticosteroids like prednisone and methylprednisolone are the primary first-line treatments, often combined with other immunosuppressants. Mild GcHD is managed with topical steroids, while systemic cases require stronger immunosuppressive therapy. Several treatments for GvHD have received FDA approval in the US, including ORENCIA (abatacept), JAKAFI/JAKAVI (ruxolitinib), IMBRUVICA (ibrutinib), and REZUROCK (belumosudil), among others. In the upcoming GvHD treatment market landscape, there are a plethora of companies investigating agents in various stages of development. To know more about the graft versus host disease clinical trials market, visit @ Graft versus Host Disease Market DelveInsight estimates that the market size for GvHD is expected to grow from USD 1.4 billion in 2024 with a significant CAGR of 8.2% by 2034. This anticipated growth is driven by advancements in treatment options, greater healthcare access, and a rising prevalence of the condition, which together foster higher demand for innovative and effective therapies. The current pipeline for graft versus host disease includes a range of drugs with diverse mechanisms of action (MoA). CSL964 (Alpha 1 Antitrypsin), EQ001 (Itolizumab; Bmab600), MaaT013, and MC0518 are the most promising drugs that are in the late-stage of development for GvHD treatment. Ongoing research and current trials have the potential to change the GvHD market. Keen to know how the GvHD market will evolve by 2034? Find out @ Graft versus Host Disease (GvHD) Market Forecast Apart from this, several GvHD drugs currently in the early stages of development include RLS-0071 by ReAlta Life Sciences, Vimseltinib by Deciphera Pharmaceuticals, ASC-930 by ASC Therapeutics, RGI-2001 by REGiMMUNE, CYP-001 by Cynata Therapeutics, arsenic trioxide (As2O3) by BioSenic (Medsenic), TRX103 (Tregs) by Tr1X, TCD601 (Siplizumab) by ITB-MED, F-652 by Evive Biotech, RHPRG4 by Lubris BioPharma, XBI302 by Xbiome, RG6287 by Genentech, ALTB-168 by AltruBio, and SER-155 by Seres Therapeutics. Now, let's examine the late-stage pipeline therapies under investigation for GvHD treatment CSL Behring's ZEMAIRA CSL964 Alpha-1 Antitrypsin, an Alpha1-Proteinase Inhibitor (A1-PI) developed by CSL Behring, is being studied for the treatment of steroid-refractory acute graft-versus-host disease (aGvHD) and for the prevention of aGvHD in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). It is currently in Phase III clinical trials for the treatment of steroid-refractory aGvHD and is also being evaluated in Phase II/III trials for its potential in preventing aGvHD. Equillium/Biocon's EQ001 EQ001 (Itolizumab; Bmab600) is a first-in-class immune-modulating antibody that targets CD6 to suppress the activation and migration of harmful T cells responsible for releasing pro-inflammatory cytokines in autoimmune and inflammatory conditions such as GvHD, moderate-to-severe uncontrolled asthma, and lupus nephritis. By acting on the CD6-ALCAM signaling pathway, Itolizumab selectively inhibits pathogenic effector T cells (Teffs) while preserving regulatory T cells (Tregs), which are essential for immune system balance. Currently, EQ001 is undergoing a Phase III clinical trial in combination with corticosteroids as a first-line therapy for GvHD.In March 2025, Equillium reported topline Phase III EQUATOR trial results for itolizumab in first-line aGVHD. While the study did not show a meaningful difference in CR or ORR at Day 29 versus placebo, itolizumab demonstrated statistically significant and clinically meaningful improvements in longer-term outcomes, including CR at Day 99, duration of response, and failure-free survival. In April 2025, the FDA declined to grant Breakthrough Therapy designation or support an Accelerated Approval pathway for itolizumab, citing limitations in the EQUATOR study data. Discover which therapies are expected to grab major GvHD market share @ Graft versus Host Disease Treatment Market MaaT Pharma's MaaT013 MaaT013 is a standardized, donor-derived microbiome ecosystem therapy characterized by high richness and diversity. It includes BUTYCORE, a consortium of bacterial species known for producing anti-inflammatory short-chain fatty acids. The therapy is designed to reestablish the balance between the patient's gut microbiome and immune system, aiming to enhance immune tolerance and responsiveness, thereby addressing steroid-resistant, gastrointestinal-dominant aGvHD. MaaT013 has been granted Orphan Drug Designation (ODD) by both the US FDA and the EMA. In December 2024, MaaT Pharma shared encouraging updated results from its Early Access Program at the ASH 2024 Annual Meeting. Subsequently, in January 2025, the company announced promising topline findings from the Phase III ARES trial, where MaaT013 achieved a 62% overall gastrointestinal response rate by Day 28, marking a significant advancement as a third-line treatment for GI-aGvHD. medac's MC0518 MC0518 is an investigational mesenchymal stromal cell (MSC) therapy developed by Medac GmbH, currently undergoing clinical trials for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) following allogeneic hematopoietic stem cell transplantation. This therapy leverages the immunomodulatory properties of MSCs to mitigate the severe inflammatory responses characteristic of SR-aGvHD, a condition where the donor's immune cells attack the recipient's tissues despite steroid treatment. The IDUNN trial, a pivotal Phase III study, is evaluating the efficacy and safety of MC0518 compared to the best available therapy (BAT) in pediatric and adolescent patients. The primary endpoint is the overall response rate (ORR) at Day 28, with secondary objectives including overall survival (OS) up to 24 months and freedom from treatment failure (FFTF) within six months. Preclinical assessments have demonstrated that MC0518 is well-tolerated, with no evidence of tumorigenicity or significant adverse effects in animal models. Discover more about drugs for GvHD in development @ Graft versus Host Disease Clinical Trials The anticipated launch of these emerging therapies for GvHD are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the GvHD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight's latest published market report, titled as Graft versus Host Disease Market Insight, Epidemiology, and Market Forecast – 2034 , will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the GvHD country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The GvHD market report offers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total allogenic transplant cases Total Graft Versus Host Disease Cases Type-specific Cases of Graft Versus Host Disease Acute Graft Versus Host Disease Cases by Grading Acute Graft Versus Host Disease Cases by Organ Involvement Chronic Graft Versus Host Disease Cases by Grading Chronic Graft Versus Host Disease Cases by Organ Involvement Total Treated Cases of Graft Versus Host Disease Mortality Adjusted Treated Cases of Graft Versus Host Disease The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM GvHD market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this GvHD market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the GvHD market. Also, stay abreast of the mitigating factors to improve your market position in the GvHD therapeutic space. Related Reports Graft versus Host Disease Epidemiology Forecast Graft versus Host Disease Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted GvHD epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan. Graft versus Host Disease Pipeline Graft versus Host Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GvHD companies, including Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical, CTI BioPharma, ViGenCell, Lipella Pharmaceuticals, Cellestia Biotech, Seres Therapeutics, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen , among others. Acute Graft versus Host Disease Pipeline Acute Graft versus Host Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute GvHD companies, including MaaT Pharma, Medac, CSL Behring, Humanigen, Ironwood Pharmaceuticals, ReAlta Life Sciences, Roche, Incyte Corporation , among others. Ocular Graft versus Host Disease Pipeline Ocular Graft versus Host Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ocular GvHD companies, including Cambium Medical Technologies, Glia LLC., Ocular Discovery, Selagine , among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期临床结果免疫疗法突破性疗法孤儿药

2023-09-14

·Pharmaceutical Technology

FDA accepts Madrigal’s liver disease therapy NDA for review

Resmetirom will target crucial underlying causes of NASH in the liver. Credit: crystal light / Shutterstock.com. The US Food and Drug Administration (FDA) has accepted for review Madrigal Pharmaceuticals ’s new drug application (NDA) for resmeritom, a liver disease therapy. Resmetirom is indicated for treating adult patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis. Recommended Reports Reports LOA and PTSR Model - Siplizumab in Liver Transplant Rejection GlobalData Reports LOA and PTSR Model - Aldafermin in Liver Cirrhosis GlobalData View all Companies Intelligence Madrigal Pharmaceuticals Inc Nash S.r.L. View all The regulator has granted priority review and set a Prescription Drug User Fee Act date of 14 March 2024. Resmetirom is a once-daily, oral, thyroid hormone receptor (THR)-β selective agonist that targets crucial underlying causes of NASH in the liver. Its clinical development programme consists of 18 clinical studies: 12 trials in Phase I, two in Phase II and four in Phase III. The company is seeking approval to treat patients with NASH and liver fibrosis under the FDA’s accelerated approval pathway. Madrigal CEO Bill Sibold stated: “NASH with liver fibrosis represents a significant unmet need in healthcare today: the disease has a serious impact on patients and, without treatment, it can lead to increased risk of cirrhosis, liver failure, liver cancer and premature mortality. “Resmetirom is a liver-directed therapy that has demonstrated the potential to treat the liver fibrosis that is associated with these negative outcomes, while resolving the underlying steatohepatitis that drives the disease.” NASH, which is a major cause of mortality related to the liver, is an advanced form of nonalcoholic fatty liver disease.

优先审批临床2期申请上市临床3期

2023-08-14

·Pharmaceutical Technology

vTv announces Phase III plans for type 1 diabetes drug cadisegliatin

Phalguni Deswal @Phalguni_GD Image Credit: Shutterstock/antoniodiaz vTv Therapeutics plans to initiate a Phase III clinical trial for cadisegliatin for treating type 1 diabetes (T1D) by the end of 2023 before filing for marketing approval with the US Food and Drug Administration (FDA). Cadisegliatin is a liver-selective glucokinase activator that is used as an adjunct therapy with insulin. It received a breakthrough therapy designation (BTD) based on its Phase II trial (NCT03335371) , which showed a 40% decrease in the frequency of severe and symptomatic hypoglycaemic events along with a decrease in serum and urine ketone events in the treatment group. Recommended Reports Reports LOA and PTSR Model - Siplizumab in Type 1 Diabetes (Juvenile Diabetes) GlobalData Reports LOA and PTSR Model - Golimumab in Type 1 Diabetes (Juvenile Diabetes) GlobalData View all Companies Intelligence vTv Therapeutics Inc Cantex Pharmaceuticals Inc VTV View all The Phase III trial will assess the reduction in the number of hypoglycaemic events with cadisegliatin, compared to placebo. This primary endpoint for the trial is recommended by the FDA as part of the approval data for T1D drugs. vTv plans to expand the drug indications for cadisegliatin to potentially include type 2 diabetes, chronic obstructive pulmonary disease, renal disease, primary mitochondrial myopathy, glioblastoma and other cancer, and related conditions. Hypoglycaemia is a significant concern for patients with T1D, as insulin treatment causes hypoglycaemia in these patients. Other drugs currently in development for treating insulin-induced hypoglycaemia include Zucara Therapeutics’ ZT-01 . vTv’s other drug azeliragon is currently in Phase II/III of development for triple-negative breast cancer by its partner, Cantex Pharmaceuticals. Azeliragon is a receptor for advanced glycation end products (RAGE) inhibitor which is being investigated for multiple indications including Alzheimer’s disease , Covid-19 complications, brain metastasis, glioblastoma, inflammatory lung disease, and other cancer indications. The company’s cash reserves stand at $12.6m as of 30 June 2023. vTv now has until 18 December 2023 to comply with Nasdaq’s Minimum Bid Requirement, which requires a company’s ordinary shares to have a value of at least $1 for a minimum of ten business days. The value of vTv’s share stands at $0.72, as of the market close on 11 August, with a market cap of $58.75m.

临床2期突破性疗法临床3期临床结果

100 项与希普利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05847	希普利珠单抗	-	DB06371

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肾移植排斥反应	临床2期	美国	Nefro Avillion Clinical Development	2026-06-29
血红蛋白SC疾病	临床2期	美国	ITB-MED AB	2023-09-28
1型糖尿病	临床2期	比利时	ITB-MED AB	2023-01-23
1型糖尿病	临床2期	意大利	ITB-MED AB	2023-01-23
1型糖尿病	临床2期	西班牙	ITB-MED AB	2023-01-23
1型糖尿病	临床2期	瑞典	ITB-MED AB	2023-01-23
1型糖尿病	临床2期	英国	ITB-MED AB	2023-01-23
斑块状银屑病	临床2期	美国	MedImmune LLC	2001-03-01
移植物抗宿主病	临床2期	-	MedImmune LLC	-
移植物抗宿主病	临床2期	-	Facultés Universitaires Catholiques de Mons	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06365437 (CTgov)	临床2期	-	33	Corticosteroids (CS)+TCD601+Tacrolimus (TAC)+Mycophenolate Mofetil (MMF) (Arm 1)	簾鏇衊選齋糧鏇顧鏇鬱(夢窪淵蓋夢選襯襯簾築) = 窪夢鑰簾襯醖齋齋夢鏇廠獵壓構積襯簾鏇糧範 (糧糧糧網範壓範構淵夢, 0.578) 更多	-	2026-03-12
NCT06365437 (CTgov)	临床2期	-	33	Corticosteroids (CS)+TCD601+Tacrolimus (TAC)+Mycophenolate Mofetil (MMF) (Arm 2)	簾鏇衊選齋糧鏇顧鏇鬱(夢窪淵蓋夢選襯襯簾築) = 憲鬱蓋衊襯夢選遞糧築廠獵壓構積襯簾鏇糧範 (糧糧糧網範壓範構淵夢, 1.96) 更多	-	2026-03-12
NCT06078696 (CD2 SCD, CTgov)	临床1/2期	血红蛋白SC疾病 \| 镰状细胞血症	1	Exchange Transfusion+Siplizumab+Mesna+Cyclophosphamide 50mg+Sirolimus Oral Tablet+Rituximab or Biosimilar	糧繭構構膚膚鑰繭願淵(觸廠網遞鏇積選蓋醖醖) = 艱廠衊膚憲簾願鬱遞獵淵窪繭鏇構鑰遞醖鑰淵 (鹹衊鹽廠衊憲範淵夢醖, 鑰膚鹹鬱範壓憲夢選繭 ~ 糧蓋淵醖積鏇糧築襯鑰) 更多	-	2026-02-27
NCT04311632 (CTgov)	临床2期	-	13	Corticosteroids (CS)+TCD601+Tacrolimus (TAC)+Mycophenolate Mofetil (MMF) (Arm 1)	範獵糧製觸構網餘齋鑰(壓淵範製膚觸壓構顧觸) = 衊鬱憲製積廠鬱鬱膚製淵淵糧網構窪鹹壓襯艱 (淵範觸簾憲鹽艱餘艱淵, 0.2) 更多	-	2025-02-27
NCT04311632 (CTgov)	临床2期	-	13	Corticosteroids (CS)+TCD601+Tacrolimus (TAC)+Mycophenolate Mofetil (MMF) (Arm 2)	範獵糧製觸構網餘齋鑰(壓淵範製膚觸壓構顧觸) = 衊鏇餘遞艱艱獵醖艱遞淵淵糧網構窪鹹壓襯艱 (淵範觸簾憲鹽艱餘艱淵, 1.1) 更多	-	2025-02-27
NCT01780454 (CTgov)	临床1/2期	终末期肾脏病	2	Thymic Irradiation+MEDI-507+Rituximab	餘鑰襯簾觸蓋構鬱構夢 = 獵範廠選構齋鑰齋鏇積艱淵繭遞廠選願網壓襯 (鏇願衊鬱獵衊淵願選製, 壓膚餘衊網艱遞鏇糧醖 ~ 構鹹鬱餘製鏇艱獵壓繭) 更多	-	2020-09-23
Pubmed	临床1期	外周T细胞淋巴瘤	-	Siplizumab	獵積餘鹽淵艱夢獵鑰鏇(鏇襯製網窪觸簾範壓鹽) = 醖鬱壓餘廠鹽範鑰膚憲構憲觸繭製鏇窪積願蓋 (壓積淵壓繭衊淵選遞憲 )	-	2018-06-03
NCT00801632 (CTgov)	临床2期	终末期肾脏病	5	steroid+MEDI-507+methylprednisolone+Cyclophosphamide+Prednisone+tacrolimus+rituximab	鹹壓蓋鏇鏇餘糧齋窪鬱 = 鹹構窪窪築鹹襯廠積鹽獵遞鹽艱範鑰觸鑰鬱憲 (繭鹽壓憲網襯獵糧鹽鏇, 襯廠鏇構積衊齋簾醖壓 ~ 齋製鑰製遞鹽鬱範簾選) 更多	-	2015-05-12
ASCO2005	临床1期	淋巴组织增生性疾病	9	Siplizumab	簾衊糧鬱夢壓願壓鹹糧(襯廠鑰壓繭壓鹽鹽衊壓) = 壓鹽衊製廠蓋蓋艱壓淵壓襯壓壓餘襯憲繭遞網 (夢鏇獵遞鬱膚糧齋廠繭, 24–99) 更多	-	2005-06-01